When the Tumor Disappears, Must the Larynx Follow?

REMATCH, a single-institution phase II study, evaluated reduced-volume surgery in patients with locally advanced head and neck cancer responding to neoadjuvant immunochemotherapy. Two-year disease-free survival was 90%, with universal laryngeal preservation. The trial advances organ preservation by reducing the extent and intensity of local therapy rather than substituting modalities.